2023.05.25 HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Membranous Nephropathy
2023.04.11 HI-Bio Announces Positive Phase 2 Data on Felzartamab for the Treatment of Primary Membranous Nephropathy
2021.07.09 ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody
2021.06.29 NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
2020.11.09 Genexine and NeoImmuneTech Announce Data Release for their Phase 1/2 Study of GX-I7/NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in patients with Triple-Negative Breast Cancer
2020.06.22 Genexine, “Hyleukin-7 (GX-I7), US clinical trial approval for COVID-19 treatment for mild patients”
